



## COMPANY OVERVIEW

Oragenics, Inc. is a biotechnology company specializing in nasal drug delivery for neurological and rare diseases. The company's lead program, ONP-002, is an intranasal neurosteroid in development for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion.

At the core of Oragenics' innovation is its proprietary intranasal drug delivery platform, designed to enhance bioavailability, precision targeting, and ease of administration. This technology enables efficient, non-invasive drug delivery to the brain, reducing systemic exposure and side effects. Beyond concussion, the platform has potential applications across a range of neurological conditions, including neurodegenerative diseases, acute brain injuries, and central nervous system disorders.

By integrating cutting-edge therapeutics with advanced drug delivery technology, Oragenics aims to transform the treatment landscape for brain-related health conditions, addressing significant unmet medical needs.

## RECENT NEWS

### Oragenics Q2 2025 Shareholder Update

Aug 11 2025, 8:45 AM EDT

## STOCK OVERVIEW

Symbol	OGEN
Exchange	NYSE American
Market Cap	4.75m
Last Price	\$1.15
52-Week Range	\$1.03 - \$75.60

08/13/2025 08:00 PM EDT

## INVESTOR RELATIONS

CG Capital  
Rich Cockrell  
T: 866.889.1972  
[ogen@cg.capital](mailto:ogen@cg.capital)

## MANAGEMENT TEAM

### Janet Huffman

Chief Executive Officer & Chief Financial Officer

### Mark Gandolfo

Project Manager

### Greg Gironda

Head of Business Development

### James P. Kelly, MA, MD, FAAN, FANA

Chief Medical Officer

### William "Frank" Peacock MD

Chief Clinical Officer

## ORAGENICS, INC.

1990 Main Street  
Suite 750  
Sarasota, FL 34236  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.